Sulbactam + ETX2514

Unassigned

New Medicines

Multi-drug resistant bacterial Acinetobacter infections

Information

New molecular entity
Entasis Therapeutics
Entasis Therapeutics

Development and Regulatory status

None
Phase II Clinical Trials
Phase III Clinical Trials

Category

Sulbactam plus a novel beta-lactamase inhibitor effective against type A, C and D beta-lactamases
In 2018, the overall incidence rate of Acinetobacter spp. bacteraemia in England was 1.5 per 100,000 - the two most frequently identified Acinetobacter species causing bacteraemia were A. lwoffii (33%) and A. baumannii (18%). Infants and older people (age >75) were most likely to be affected. [7]
Multi-drug resistant bacterial Acinetobacter infections
Intravenous